GLTO

Galecto, Inc. is a clinical-stage biotechnology company developing molecules to target galectin-3 and other galectins for the treatment of fibrotic and inflammatory diseases. The company's lead product candidates include GB0139, a small molecule galectin-3 inhibitor being developed for idiopathic pulmonary fibrosis and other fibrotic diseases. Galecto is also developing GB1211, an oral galectin-3 inhibitor, and GB2064, a selective galectin-1 inhibitor for cancer indications. The company's research is based on the role of galectins in disease pathogenesis, particularly their involvement in fibrosis, inflammation, and immune system dysfunction. Galecto has established collaborations with academic institutions and pharmaceutical companies to advance its pipeline. The company's development programs address serious diseases with limited treatment options including various lung fibrosis conditions and liver fibrosis.